Shijiazhuang Yuanheng Pharmaceutical Group (01093.HK): The phase I clinical trial of SYS 6063 for the treatment of refractory systemic lupus erythematosus has officially launched at the first center in China.

The Zhuhai Finance APP reports that Shanghai Pharma Group (01093.HK) announced that the Phase I clinical trial of SYS6063, developed by the group for the treatment of refractory systemic lupus erythematosus (SLE), has officially launched at the first center in China.